Last updated on July 2020

Phase 3 Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)

Brief description of study

The primary objective of this study was to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12.

Detailed Study Description

The study had a Screening period (minimum of 7 days and up to approximately 14 days) to determine participant inclusion, a Baseline visit including 24 hours of objective measurement of cough. The study had two treatment periods (a main 12-week treatment period and a 40-week extension period), and a 14-day follow-up period.

Clinical Study Identifier: NCT03449134

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.